Evidence map›Paper›PMID 28534511›Full record

ArticleOncogene2017

Stromal-derived IGF2 promotes colon cancer progression via paracrine and autocrine mechanisms.

C Unger, N Kramer, D Unterleuthner, M Scherzer, A Burian, A Rudisch, M Stadler, M Schlederer, D Lenhardt, A Riedl and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 84 citations in OpenAlex.

  1. Article
  2. Article
  3. Systemic Therapy for Solitary Fibrous Tumor.Current treatment options in oncology · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Pharmaceuticals (Basel, Switzerland) · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. IGF-1R targeting in cancer - does sub-cellular localization matter?Journal of experimental & clinical cancer research : CR · 2023
    Review
  17. IL1R1Nature communications · 2023
    Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

C UngerInstitute of Medical Genetics, Medical University of Vienna, Vienna, Austria.
N KramerInstitute of Medical Genetics, Medical University of Vienna, Vienna, Austria.
D UnterleuthnerInstitute of Medical Genetics, Medical University of Vienna, Vienna, Austria.
M ScherzerInstitute of Medical Genetics, Medical University of Vienna, Vienna, Austria.
A BurianInstitute of Medical Genetics, Medical University of Vienna, Vienna, Austria.
A RudischBoehringer Ingelheim RCV GmbH &Co KG, Vienna, Austria.
M StadlerInstitute of Medical Genetics, Medical University of Vienna, Vienna, Austria.
M SchledererInstitute of Clinical Pathology, Medical University of Vienna, Vienna, Austria.
D LenhardtOncotest GmbH, Am Flughafen 12, Freiburg, Germany.
A RiedlInstitute of Medical Genetics, Medical University of Vienna, Vienna, Austria.
S WalterInstitute of Medical Genetics, Medical University of Vienna, Vienna, Austria.
A WernitznigBoehringer Ingelheim RCV GmbH &Co KG, Vienna, Austria.
L KennerInstitute of Clinical Pathology, Medical University of Vienna, Vienna, Austria.
M HengstschlägerInstitute of Medical Genetics, Medical University of Vienna, Vienna, Austria.
J SchülerOncotest GmbH, Am Flughafen 12, Freiburg, Germany.
W SommergruberBoehringer Ingelheim RCV GmbH &Co KG, Vienna, Austria.
H DolznigInstitute of Medical Genetics, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-6063-3585
Medical University of Vienna · ATBoehringer Ingelheim (Austria) · ATUniversity of Veterinary Medicine Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The insulin-like growth factor (IGF)2/IGF1 receptor (IGF1R) signaling axis has an important role in intestinal carcinogenesis and overexpression of IGF2 is an accepted risk factor for colorectal cancer (CRC) development. Genetic amplifications and loss of imprinting contribute to the upregulation of IGF2, but insufficiently explain the extent of IGF2 expression in a subset of patients. Here, we show that IGF2 was specifically induced in the tumor stroma of CRC and identified cancer-associated fibroblasts (CAFs) as the major source. Further, we provide functional evidence that stromal IGF2, via the paracrine IGF1R/insulin receptor axis, activated pro-survival AKT signaling in CRC cell lines. In addition to its effects on malignant cells, autocrine IGF2/IGF1R signaling in CAFs induced myofibroblast differentiation in terms of alpha-smooth muscle actin expression and contractility in floating collagen gels. This was further augmented in concert with transforming growth factor-β (TGFβ) signaling suggesting a cooperative mechanism. However, we demonstrated that IGF2 neither induced TGFβ/smooth muscle actin/mothers against decapentaplegic (SMAD) signaling nor synergized with TGFβ to hyperactivate this pathway in two dimensional and three dimensional cultures. IGF2-mediated physical matrix remodeling by CAFs, but not changes in extracellular matrix-modifying proteases or other secreted factors acting in a paracrine manner on/in cancer cells, facilitated subsequent tumor cell invasion in organotypic co-cultures. Consistently, colon cancer cells co-inoculated with CAFs expressing endogenous IGF2 in mouse xenograft models exhibited elevated invasiveness and dissemination capacity, as well as increased local tumor regrowth after primary tumor resection compared with conditions with IGF2-deficient CAFs. In line, expression of IGF2 correlated with elevated relapse rates and poor survival in CRC patients. In agreement with our results, high-level coexpression of IGF2 and TGFβ was predicting adverse outcome with higher accuracy than increased expression of the individual genes alone. Taken together, we demonstrate that stroma-induced IGF2 promotes colon cancer progression in a paracrine and autocrine manner and propose IGF2 as potential target for tumor stroma cotargeting strategies.

Indexed as

AnimalsAutocrine CommunicationCaco-2 CellsCell Line, TumorColorectal NeoplasmsDisease ProgressionFemaleFibroblastsHCT116 CellsHeterograftsHumansInsulin-Like Growth Factor IIMiceMice, Inbred NODParacrine CommunicationReceptor, IGF Type 1IGF1R protein, humanIGF2 protein, humanInsulin-Like Growth Factor IIReceptor, IGF Type 1Receptors, Somatomedin

Identifiers

PMID28534511
OpenAlexW2620241956

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.